RYDAPT (midostaurin) 

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:

  • Indicated for the treatment of adults patients with:
    • Newly diagnosis acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. (Rydapt is not indicated as a single-agent induction therapy for the treatment of patients with AML.)
    • Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)

Patients must meet the following criteria for the indiciation(s) above:

  • Prescribed by an oncologist, AND
  • 18 years or older, AND
  • Confirmed diagnosis:
    • Acute Myeloid Leukemia (AML) that is FLT3-mutation positive
    • Aggressive Systemic Mastocytosis (ASM)
    • Systemic Mastocytosis Associated with Acute Hematologic Neoplasm (SM-AHN)
    • Mast Cell Leukemia (MCL), AND
  • For FLT3-mutation positive AML only: member is newly diagnosed, and Rydapt will be used in combination with standard cytarabine + daunorubicin induction and cytarabine consolidation chemotherapy in newly diagnosed FLT3-mutation positive AML.  (Rydapt is not indicated as a single-agent induction therapy for the treatment of patients with AML.)

Dosing:

  • AML: 50 mg orally twice daily with food on days 8 to 21 of each cycle of induction with cytarabine and daurorubicin and on days 8 to 21 of each cycle of consolidation with high-dose cytarabine
  • ASM, SM-AHN, MCL: 100mg orally twice daily with food

Approval:

  • 1 year

Last review date: December 3, 2018

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone